Baird raised the firm’s price target on Argenx to $515 from $490 and keeps an Outperform rating on the shares. The firm said the key updates from earnings were a strong 2Q24 revenue of $489M, far higher than consensus of $439M, and the announcement of a decision to advance ITP into a confirmatory study for the US following discussions with the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX: